Source: FDA Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDAs Ongoing Evaluation of Reports of Suicidal Thoughts or Actions ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs
Especially if this difference costs indefinite waiting
Eli Lilly has indicated that the broader TRIUMPH program, which includes trials in obesity (TRIUMPH-1), type 2 diabetes (TRIUMPH-2 and TRIUMPH-3), and obesity-related conditions (TRIUMPH-4), is progressing on schedule
Consequently, the variability in potency and dosage can pose risks, making it essential for healthcare providers to closely monitor patients receiving compounded versions
By improving insulin secretion and reducing glucose production, it helps maintain better glycemic control, reducing the likelihood of diabetes-related complications